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Abstract
Aims/hypothesis We aimed to investigate whether diabetes cases
detected through screening have better health outcomes than
clinically detected cases in a population-based cohort of adults
who were eligible to be screened for diabetes at 10 year intervals.
Methods The Västerbotten Intervention Programme is a
community- and individual-based public health programme
in Västerbotten County, Sweden. Residents are invited to
clinical examinations that include screening for diabetes by
OGTTs at age 30, 40, 50 and 60 years (individuals eligible
for screening, n = 142,037). Between 1992 and 2013, we
identified 1024 screen-detected cases and 8642 clinically
detected cases of diabetes using registry data. Clinically
detected individuals were either prior screening participants
(n = 4506) or people who did not participate in screening
(non-participants, n = 4136). Study individuals with diabetes
were followed from date of detection until end of follow-up,
emigration, death or incident cardiovascular disease (CVD),
renal disease or retinopathy event, and compared using Cox
proportional hazard regression adjusted for calendar time, age
at detection, year of detection, sex and socioeconomic status.
Results The average age at diabetes diagnosis was 4.6 years
lower for screen-detected individuals comparedwith clinically
detected individuals. Overall, those who were clinically
detected had worse health outcomes than those who were
screen-detected (HR for all-cause mortality 2.07 [95%
CI 1.63, 2.62]). Compared with screen-detected study
individuals, all-cause mortality was higher for clinically
detected individuals who were screening non-participants
(HR 2.31 [95% CI 1.82, 2.94]) than for those clinically
detected who were prior screening participants (HR 1.70
[95% CI 1.32, 2.18]). Estimates followed a similar pattern
for CVD, renal disease and retinopathy.
Conclusions/interpretation Individuals with screen-detected
diabetes were diagnosed earlier and appeared to fare better
than those who were clinically detected with regard to
all-cause mortality, CVD, renal disease and retinopathy.
How much of these associations can be explained by earlier
treatment because of screening rather than healthy user bias,
lead time bias and length time biaswarrants further investigation.
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Introduction
More than 1 million adults in the UK and 160,000 adults in
Sweden are estimated to be living with undiagnosed diabetes
[1], which is potentially detectable by screening. In screening
for type 2 diabetes, one cluster-randomised controlled trial in a
high-risk UK population (Anglo–Danish–Dutch study of
intensive treatment in people with screen-detected diabetes
in primary care [ADDITION]-Cambridge [2]) and a
controlled trial in a high-risk Danish population
(ADDITION-Denmark [3]) found no effect on mortality in
the population after approximately 10 years. One cohort study
in an average-risk UK population (the Ely cohort) reported a
reduction of mortality in 1990–1999, but no effect 10 years
later [4]. In the Ely cohort, the average lead time for a diabetes
diagnosis following screening was estimated at 3.3 years, but
this was not associated with lower incidence of adverse health
outcomes for individuals detected earlier through screening
[5]. A study in Sweden compared people with diabetes
detected through an opportunistic screening programme with
those detected clinically in the same eligible population and
found no difference in age at diagnosis or any effect on health
outcomes for screen-detected individuals [6]. However, in
ADDITION-Denmark, a lead time of 2.2 years was associated
with lower mortality and cardiovascular disease (CVD) risk
among those in the screened group [7].
One review found that the positive predictive values of a
single biochemical screening test for diabetes ranged between
24% and 48% [8], meaning that more than half of those with
positive screening tests probably have only transient
non-diabetic hyperglycaemia. Although it is known that,
compared with normoglycaemia, those with non-diabetic
hyperglycaemia have an increased risk of CVD and death
[9], the fate of those with unconfirmed diabetes following a
positive test result has not specifically been studied.
Following reports in the 1970s of relatively high mortality
from CVD in the Swedish county of Västerbotten, a
community public health intervention programme was
launched [10]. The Västerbotten Intervention Programme
(VIP) was first implemented in 1985 and reached full
coverage in 1992. There is some evidence that the overall
public health programme has had a positive impact on
all-cause and CVD mortality [11]. VIP has both a community
and an individual focus, with invitations to standardised health
examinations in primary healthcare [10]. Crucially, these
include OGTTs, which allows us to study the VIP as a model
for an organised systematic universal diabetes population
screening programme.
We aimed to investigate the association between screen
detection of type 2 diabetes and all-cause mortality,
CVD events, renal disease and retinopathy in this
population-based cohort of adults eligible to be screened
at 10 year intervals. The secondary aim was to investigate
the rate of these outcomes in unconfirmed screen-positive
cases.
Methods
The VIP Since 1985, residents of Västerbotten County
have been eligible for invitation to standardised health
examinations at the age of 30 (until 1995), 40, 50 and 60 years,
as previously described in detail [10]. Briefly, at every
VIP examination, participants are asked to complete a
comprehensive questionnaire that covers, among other things,
lifestyle behaviour and health status; this, together with OGTT
results, is used as the basis for a motivational health
promotion dialogue. Individuals found to have non-diabetic
hyperglycaemia receive referrals for a follow-up visit with a
nurse, and individuals found to have diabetes are referred to
primary care for confirmatory testing and treatment [10].
The overall rate of participation at the first eligible VIP
examination over the study period has ranged from 48% to
67% [12]. Objectively measured data, such as BMI and blood
glucose measurements, and associated questionnaire data
collected in the VIP health examinations may be linked to
local and national registers using the Swedish personal
identification number [13].
Ethical approval for this study was granted by the Regional
Ethical Review Board, Umeå, Sweden (Dnr 2013-395-31M,
Dnr 2014-410-32M).
Eligible study population Eligible individuals (n = 142,037)
were identified in the Population Register that is maintained
by the Swedish Tax Agency [14]. They were resident in
Västerbotten County between 1992 and 2013, born between
1932 and 1971, and aged 30 years or older with sufficient
information available to enable record linkage to other
population-based registers (Fig. 1). We excluded individuals
who had a record of prevalent diabetes (n = 1761), leaving a
study population of 140,276 individuals eligible for screening
among whom incident diabetes was identified. We followed
up the study individuals for detection of diabetes from 1
January 1992, their 30th birthday or the date of their move
to Västerbotten County, until 31 December 2013, death or
emigration, whichever came first.
Screen-detected diabetes In the study population, 94,067
individuals attended at least one VIP examination, which
corresponds to a participation rate of 67.1% (Fig. 1). Each
health examination included an OGTT using a 75 g oral
glucose load [15]. In total, 16,214 individuals had a
non-diabetic hyperglycaemic OGTT measurement (fasting
or 2 h capillary plasma blood glucose of 6.1–6.9 mmol/l or
8.9–12.1 mmol/l, respectively), and 3483 individuals had an
OGTT measurement indicative of diabetes (defined according
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to current diagnostic criteria as a fasting or 2 h capillary
plasma blood glucose level of ≥ 7.0 mmol/l or ≥ 12.2 mmol/l,
respectively) without any prior record of a diabetes diagnosis.
Among participants with diabetes-indicative OGTT
measurements, 1024 (29.4%) were confirmed as having type
2 diabetes within 1 year in at least one medical or prescription
record (see details below); the majority were confirmed in
either the Västerbotten County Medical Record system
(n = 486, 47.5%) or the Diabetes Register in Northern
Sweden (DiabNorth; n = 425, 41.5%); 1403 (40.3%)
individuals did not have any record of a diabetes diagnosis
besides one OGTT in the diabetic range and were, thus, classed
as unconfirmed screen-positive participants (Fig. 1). In
addition, 776 (22.3%) individuals had an OGTT indicative of
diabetes but were only confirmed as having diabetes after more
than 1 year and were thus considered to have clinically detected
diabetes (see below), and 280 individuals had a medical record
of a type of diabetes other than type 2, for example type 1
diabetes or gestational diabetes (Fig. 1).
Clinically detected diabetes In total, 8642 individuals with
diabetes were identified in five sources of medical and
prescription records (numbers and percentages refer to those
with their earliest date of diagnosis in the source): (1)
DiabNorth (n = 1205, 13.9%), a register of validated diabetes
diagnoses in VIP until 2012 [16]; (2) the National Diabetes
Register (n = 603, 7.0%), a resource linked to primary care
that was initiated in 1996 [17] (coverage of the National
Diabetes Register in Västerbotten County ranged between
50% and over 70% of individuals with diabetes registered
Fig. 1 Flow chart describing the study population. The prevalent
diabetes-free study population (N = 140,276) was eligible for screening;
46,209 individuals did not participate in screening and 94,067 did.
Among the screening participants, 16,214 had non-diabetic
hyperglycaemia (n = 1898 were later detected clinically) and 3483
screened positive for diabetes. Of those who screened positive, the
diagnosis was confirmed within 1 year in 1024 individuals, and remained
unconfirmed in 1403 (n = 280were found to have diabetes other than type
2). A total of 776 individuals were clinically detected after having
screened positive for diabetes more than 1 year previously, 1716 were
clinically detected after having normoglycaemia in screening, and 116
were clinically detected after participating in a health examination
without completing an OGTT. In total, among all screening participants,
n = 4506 cases of diabetes were clinically detected, whilst in screening
non-participants, 4136 cases of diabetes were clinically detected. Dashed
lines indicate that downstream boxes do not include all individuals in
upstream box, solid lines indicate that all individuals in upstream box
are accounted for in downstream boxes
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[18]); (3) the Västerbotten County Medical Record system
(n = 4984, 57.7%), which includes records of all primary care
visits in the county since 2006, with partial coverage since
1993; (4) the Prescribed Drugs Register (n = 896, 10.4%),
which includes records of all dispensed prescription drugs
since 1 July 2005 (a diabetes record defined as dispensing of
any drug with an Anatomical Therapeutic Chemical code
A10) [19]; and (5) the National Patient Register, which
includes all inpatient discharge records since 1987 (n = 858,
9.9%), with partial national coverage since 1964, and
outpatient records since 2001 (n = 96, 1.1%) (diabetes defined
as a record with a primary or contributory diagnosis of
diabetes (ICD codes 250 [revision 9; www.icd9data.com/
2007/Volume1] or E11, E13 or E14 [revision 10; www.who.
int/classifications/icd/en/]) [20]. These sources were also used
to confirm screen-detected diabetes cases (see above). Using
capture–recapture [21], we estimate that 96.9% of diabetes
cases in the population were identified using a combination
of these sources.
Individuals with clinically detected diabetes were divided
into two groups based on participation in VIP screening before
the first detection of diabetes; VIP participants were further
divided into three groups. A total of 4506 (52.1%) individuals
with diabetes had participated in the VIP at least once before
the date of detection of diabetes and had had either: (1) an
OGTTmeasurement indicative of diabetes (if more than 1 year
before detection, n = 776); (2) a non-diabetic hyperglycaemic
OGTT (n = 1898); or (3) a normoglycaemic OGTT (n = 1716)
(n = 116 had participated in the VIP but had missing OGTT
data). The remaining 4136 (n = 47.9%) individuals with
clinically detected diabetes never participated in VIP
screening, despite being eligible to do so, before the detection
of diabetes (Fig. 1).
Events and outcomes The primary outcome was date of
death as identified by record linkage to the Total Population
Register (Statistics Sweden) [14]. Secondary outcomes were
dates of incident CVD events (myocardial infarction, heart
failure, stroke or peripheral arterial disease), incident renal
disease or incident retinopathy. All disease events were
identified in the National Patient Register as well as the
Cause of Death Register, which has had complete coverage
since 1961 [22]. See electronic supplementary material (ESM)
Table 1 for a detailed list of all the ICD-9 and ICD-10 codes
used to classify events.
Other variables Sex and date of birth were taken from the
Total Population Register [14]. Socioeconomic status (SES)
was categorised into four levels (manual workers, non-manual
workers, self-employed and undefined) in the 1990 census.
For 1561 individuals who had missing information on SES,
we imputed values using single imputation (the ‘ice’
command in Stata [version 14.2; StataCorp, College Station,
TX, USA]) based on the variables sex, birth date, VIP
participation (yes/no) and international migration status.
Prior CVD events were ascertained in the National Patient
Register and defined as above if they occurred before or on
the same date as diabetes detection. For VIP participants,
height, weight, BP and serum total cholesterol were
objectively measured at VIP examinations [10]. BMI was
calculated as the weight (kg) divided by height squared
(m2). The VIP questionnaire includes the question, ‘how has
your health been in the past year?’; we dichotomised the
response alternatives ‘good’, ‘pretty good’, ‘somewhat good’,
‘pretty bad’ and ‘bad’ into ‘overall good’/‘overall bad’ [23].
Statistical analysis Individuals with diabetes were followed
up from date of first detection of diabetes (i.e. the date of VIP
screening for screen-detected diabetes, or the date of the first
diabetes record for clinically detected diabetes) until 31
December 2013, date of death, emigration or date of outcome
event depending on the model. Crude incidence rates and
mortality rates were calculated as events divided by time at
risk scaled to 1000 person-years. Directly standardised
incidence rates and standardised mortality rates were
calculated with weights derived from the follow-up time and
age and sex distribution in the total study population
(n = 140,276) as reference. Associations between mode of
detection of diabetes and outcomes were assessed using Cox
proportional hazard regression, generating HRs and 95% CIs.
All models used calendar time as the underlying time scale
and were adjusted for age at and calendar year of diabetes
detection as continuous variables, sex and SES in 1990.
Differences in biomarkers measured at concurrent or
previous VIP examination between individuals with screen-
detected diabetes vs those with unconfirmed screen-positive
and clinically detected diabetes who were screening partici-
pants were tested using the t test for continuous variables, and
the χ2 test for categorical variables. To disentangle the
contributions of early treatment and length time bias to the
difference in outcome rates between screen-detected and
clinically detected individuals with diabetes who had been
screening participants, we conducted two sensitivity analyses:
(1) main analysis further adjusted for prior CVD event status;
and (2) main analysis further adjusted for prior CVD event
status, and the following variables measured at concurrent or
previous VIP examination—BMI, diastolic and systolic BP,
serum total cholesterol, self-reported health status and time
from screening to diabetes detection in years. All analyses
were performed in Stata version 14.2 (StataCorp).
Results
We identified 9666 diabetes cases in total, constituting a
cumulative incidence of 6.9% in the study population. Those
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with screen-detected diabetes were on average 4.6 years
younger at diagnosis than those with clinically detected
diabetes, 6.4 years younger than clinically detected
individuals who were screening participants and 2.8 years
younger than clinically detected individuals who were
screening non-participants (Table 1). There was a substantial
difference in the proportion of individuals who had
experienced a CVD event prior to the date of detection of
diabetes between those who had screen-detected diabetes
(5.4%) and those with clinically detected diabetes (15. 2%).
Among all individuals with clinically detected diabetes, 227
(2.6%) had a CVD event recorded on the same date as the date
of detection of diabetes (data not shown).
Among clinically detected individuals with diabetes who
were screening participants, those who had a previous diabetic
or non-diabetic hyperglycaemic screening result were
diagnosed on average 6.3 and 6.9 years, respectively, after
their last screening. Those who had previously had a
normoglycaemic screening result were diagnosed with
diabetes on average 10.3 years after their last screening;
among individuals who had screened negative for diabetes
or non-diabetic hyperglycaemia, 13 (0.76%) were diagnosed
with diabetes within 1 year (data not shown). Overall, among
screening participants, those with screen-detected diabetes
had similar mean levels of self-reported bad health and BP
to those with clinically detected diabetes and had had a
diabetic or non-diabetic hyperglycaemic OGTT result at
previous screening (Table 2). For serum total cholesterol, the
average levels were also very similar (≤ 0.2 mmol/l difference
between confirmed screen-detected diabetes and the other
groups), although the differences were statistically significant.
Compared with screen-detected diabetes, mean BMI was
1.1 kg/m2 lower among clinically detected individuals
who were screening participants. Among screen-detected
individuals with diabetes, 443 (43.3%) reported a family
history of diabetes in the VIP questionnaire; the corresponding
number was 1519 (33.7%) among clinically detected
individuals who were screening participants (data not shown).
Table 1 Descriptive statistics of participants with type 2 diabetes mellitus, VIP 1992–2013
Variable Incident clinically detected diabetes
Total Confirmed screen-
detected diabetes
Unconfirmed screen-
positive individuals
All Screening
participants
Screening non-
participants
Total 11,069 (100.0) 1024 (9.3) 1403 (12.7) 8642 (78.1) 4506 (40.7) 4136 (37.4)
Men 6459 (58.4) 595 (58.1) 783 (55.8) 5081 (58.8) 2572 (57.1) 2509 (60.7)
Women 4610 (41.6) 429 (41.9) 620 (44.2) 3561 (41.2) 1934 (42.9) 1627 (39.3)
Age at detection, years
Mean ± SD (median) 58.5 ± 9.7 (59.9) 55.1 ± 6.4 (59.8) 53.4 ± 8.0 (59.7) 59.7 ± 9.9 (60.2) 61.5 ± 9.0 (62.2) 57.9 ± 10.4 (58.4)
30–39 246 (2.2) 0 (0.0) 27 (1.9) 219 (2.5) 20 (0.4) 199 (4.8)
40–49 1410 (12.7) 82 (8.0) 220 (15.7) 1108 (12.8) 441 (9.8) 667 (16.1)
50–59 3296 (29.8) 335 (32.7) 406 (28.9) 2555 (29.6) 1222 (27.1) 1333 (32.2)
60–69 4494 (40.6) 607 (59.3) 750 (53.5) 3137 (36.3) 1851 (41.1) 1286 (31.1)
70+ 1623 (14.7) – – 1623 (18.8) 972 (21.6) 651 (15.7)
Year of detection
1992–1999 2012 (18.2) 217 (21.2) 369 (26.3) 1426 (16.5) 352 (7.8) 1074 (26.0)
2000–2006 3841 (34.7) 369 (36.0) 537 (38.3) 2935 (34.0) 1426 (31.6) 1509 (36.5)
2007–2013 5216 (47.1) 438 (42.8) 497 (35.4) 4281 (49.5) 2728 (60.5) 1553 (37.5)
SES in the 1990 censusa
Manual workers 5516 (49.8) 479 (46.8) 701 (50.0) 4337 (50.2) 2259 (50.1) 2089 (50.5)
Non-manual workers 4235 (38.3) 411 (40.1) 543 (38.7) 3285 (38.0) 1737 (38.5) 1534 (37.1)
Self-employed 744 (6.7) 82 (8.0) 103 (7.3) 562 (6.5) 305 (6.8) 264 (6.4)
Undefined 574 (5.2) 52 (5.1) 56 (4.0) 458 (5.3) 205 (4.5) 249 (6.0)
Prior CVD eventb 1420 (12.8) 55 (5.4) 53 (3.8) 1312 (15.2) 673 (14.9) 639 (15.4)
Data are presented as n (%), unless otherwise stated
Unconfirmed screen-positive individuals only had a diabetic screening result, whereas confirmed screen-detected individuals had a diabetic screening
result and a medical or prescription record of diabetes within 1 year. Those with clinically detected diabetes were identified in five sources of medical and
prescription records, unrelated to screening
a SES imputed for n = 1561 individuals who had missing information
b Previous CVD events included those coinciding with the date of diabetes detection (n = 227)
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The standardised mortality rate was 3.2/1000 person-years
for all VIP participants, 8.4/1000 person-years for all
non-participants and 3.0/1000 person-years for known
normoglycaemic VIP participants (data not shown). Average
follow-up time was 8.7 (median 7.8) years for individuals with
screen-detected diabetes, and 7.2 (median 6.2) years for those
who were clinically detected diabetes, after their date of
detection (maximum 21.9 years). Those with screen-detected
diabetes had a consistently lower rate of all-cause mortality,
CVD, renal disease and retinopathy than those with clinically
detected diabetes (Table 3). Among clinically detected
individuals with diabetes, screening participants had
lower rates of all outcomes compared with screening
non-participants. There was a clear pattern of HR; compared
with screen-detected diabetes, those who had clinically
detected diabetes who were screening participants had an
increased risk of poor health outcomes (e.g. all-cause
mortality HR 1.70 [95% CI 1.32, 2.18]), and clinically
detected individuals who were screening non-participants
had an even higher risk of poor health outcomes (e.g.
all-cause mortality HR 2.31 [95% CI 1.82, 2.94]) (Table 4).
The results were similar over the course of follow-up; a total
of 3397 (30.7%) individuals with diabetes, including 394
screen-detected individuals, were followed for 10 years or
longer. The HR for all-cause mortality after 10 years was
1.91 (95% CI 1.27, 2.85) for clinically detected vs
screen-detected diabetes cases.
Among clinically detected individuals with diabetes who
were screening participants, those who had had previous
normoglycaemia tended to have higher rates of adverse health
outcomes, with the exception of retinopathy, compared with
those who had had previous OGTTs indicative of diabetes or
non-diabetic hyperglycaemia (Table 3). In general, those who
had had previous OGTT measurements in the diabetic range
and those who had had previous non-diabetic hyperglycaemia
had very similar HRs (e.g. all-cause mortality HR 1.61 and
1.59, respectively), whereas those who had had previous
normoglycaemia had higher risks for all outcomes (e.g.
all-cause mortality HR 2.05 [95% CI 1.56, 2.70]), with the
exception of retinopathy (Table 4).
To explore whether some of the effect of mode of detection
of diabetes among participants in screening could be
explained by differences in an individual’s health status, we
conducted sensitivity analyses adjusting for presence of a
prior CVD event, and additionally for several biomarkers
measured at previous screening (listed in Table 2), as well as
time since previous screening (ESM Table 2). As a result,
when adjusting for prior CVD event status, all estimates were
attenuated but, with the exception of the HR of CVD events
(HR 1.16 [95% CI 0.95, 1.41]), remained significant.
Estimates were further attenuated when adjusting for
additional biomarkers.
Unconfirmed screen-positive individuals were on average
1.7 years younger at the date of their diabetes-indicative
OGTTscreening result than those who had a confirmed diagno-
sis (Table 1); they had a higher mortality rate than for screen-
detected diabetes, but a lower incidence rate for all other out-
comes, and a very low incidence rate for renal disease and ret-
inopathy (Table 3). Compared with confirmed screen-detected
diabetes cases, unconfirmed screen-positive cases had higher
Table 3 Crude and standardised incident event and mortality rates among individuals with type 2 diabetes mellitus, VIP 1992–2013
Variable Deaths CVD events Renal disease Retinopathy
n MR StdMR n IR StdIR n IR StdIR n IR StdIR
Confirmed screen-detected diabetes 73 8.2 4.2 128 15.5 8.7 39 4.4 3.3 70 8.1 6.3
Unconfirmed screen-positive individuals 139 10.4 5.9 141 11.0 5.8 23 1.7 0.9 9 0.7 0.4
Incident clinically detected diabetes 1330 21.4 15.5 1704 30.5 21.9 649 10.8 9.3 757 12.7 12.7
Screening participants 515 18.8 11.5 680 27.1 19.8 258 9.6 8.6 279 10.5 9.7
Previous diabetes-indicative OGTT > 1 year before detection 93 17.0 9.4 114 22.9 13.7 41 7.7 5.0 70 13.3 9.9
Previous non-diabetic hyperglycaemia 194 16.4 12.0 267 24.5 21.0 100 8.7 10.5 103 9.0 10.3
Previous normoglycaemia 206 22.0 12.5 275 32.3 20.4 102 11.2 7.9 91 10.0 8.8
Screening non-participants 815 23.4 18.4 1024 33.3 25.5 391 11.6 10.2 478 14.6 14.2
Incidence rate and mortality rate are reported per 1000 person-years. Age- and sex-standardised mortality rate and incidence rate are calculated with the
total study population as reference
Rates do not include events that coincide with the date of diabetes detection
CVD, renal and retinal events were detected in the National Patient Register and the Cause of Death Register
Unconfirmed screen-positive individuals only had a diabetic screening result, whereas confirmed screen-detected individuals had a diabetic screening
result and a medical or prescription record of diabetes within 1 year. Those with clinically detected diabetes were identified in five sources of medical and
prescription records, unrelated to screening
IR, incidence rate; MR, mortality rate; StdIR, standardised incidence rate; StdMR, standardised mortality rate
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risk of all-cause mortality (HR 1.35 [95% CI 1.01, 1.79]) but
lower risk of CVD (HR 0.77 [95% CI 0.60, 0.98]) and substan-
tially lower HR of renal disease (HR 0.41 [95% CI 0.25, 0.69])
and retinopathy (HR 0.08 [95% CI 0.04, 0.16]) (Table 4).
Discussion
In this study of a population included in an organised univer-
sal screening programme for diabetes, we found that a diag-
nosis of diabetes can be brought forward by an average of
4.6 years by screening asymptomatic individuals, and that
screen-detected individuals appear to fare better than those
with clinically detected diabetes after their diagnosis.
The lead time is somewhat longer than the 3.3 years and
2.2 years estimated in previous studies [5, 7]. There are
important differences with regards to screening interval and
analytical approach between this study and the previous
studies that may explain this difference. In the Ely cohort,
one-third of the population was randomly invited to
participate in screening for diabetes in 5 year intervals
(screened population), and two-thirds of the cohort were not.
However, at the third screening round, one-third of the
population initially not included in the screening arm were
randomly invited to take part (‘unscreened’ population).
Lead time was calculated as the difference in median diabetes
duration for the screened and ‘unscreened’ population, both of
which included screen- and clinically detected individuals. In
the ADDITION-Denmark study, high-risk individuals were
invited to screening at one time-point, and lead time was
calculated as the difference in median diabetes duration be-
tween screen-detected individuals vs. clinically detected
individuals in the whole group eligible to be screened. In this
study, we compared age at detection in individuals with
screen-detected vs clinically detected diabetes who had been
eligible to be screened in 10 year intervals.
We found that those with screen-detected diabetes had
lower rates of all-cause mortality and incident CVD, renal
disease and retinopathy than those with clinically detected
diabetes. This is in line with the modelled estimated reduction
in CVD events caused by earlier routine treatment that was
found in a previous study [24]. It is possible that the observed
effect may be caused by the treatment that screen-detected
individuals presumably received earlier than those whose
diabetes had been clinically detected, but there are three
important biases that may explain some of the effect.
The first is healthy user bias. Clinically detected
individuals who were screening non-participants were
detected on average 3.6 years earlier than clinically detected
individuals who were screening participants, but despite being
diagnosed with diabetes earlier, they had consistently worse
health outcomes. On average, VIP non-participants had more
than twice the rate of all-cause mortality than VIP participants
when comparing age- and sex-standardised mortality rates.
Similarly, it has been shown that in screening for human
papilloma virus, regular non-attenders have about a twofold
higher all-cause mortality than regular attenders [25].
Although VIP is not a screening programme for diabetes, it
is likely that the individual choice to attend the clinical
examinations would be guided by similar behaviour to the
choice to attend systematic organised screening programmes.
In the VIP, participation has been linked to marital status and
higher income, but not education [12].
Second, there is length time bias. The idea that slowly
developing disease with a longer asymptomatic preclinical
screen-detectable course is also more likely to have a long
Table 4 Associations betweenmode of detection of type 2 diabetesmellitus and death, incident CVD events, renal disease or retinopathy, VIP 1992–2013
Variable All-cause mortality,
HR (95% CI)
CVD events,
HR (95% CI)
Renal disease,
HR (95% CI)
Retinopathy,
HR (95% CI)
Confirmed screen-detected diabetes 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref)
Unconfirmed screen-positive individuals 1.35 (1.01, 1.79) 0.77 (0.60, 0.98) 0.41 (0.25, 0.69) 0.08 (0.04, 0.16)
Incident clinically detected diabetes 2.07 (1.63, 2.62) 1.55 (1.29, 1.86) 2.26 (1.64, 3.13) 1.66 (1.30, 2.13)
Screening participants 1.70 (1.32, 2.18) 1.25 (1.03, 1.52) 1.89 (1.34, 2.66) 1.38 (1.06, 1.80)
Previous diabetes-indicative OGTT > 1 year before detection 1.61 (1.18, 2.20) 1.11 (0.86, 1.43) 1.58 (1.02, 2.45) 1.73 (1.24, 2.42)
Previous non-diabetic hyperglycaemia 1.59 (1.21, 2.09) 1.18 (0.95, 1.46) 1.76 (1.21, 2.56) 1.19 (0.87, 1.61)
Previous normoglycaemia 2.05 (1.56, 2.70) 1.47 (1.19, 1.83) 2.20 (1.51, 3.20) 1.35 (0.98, 1.85)
Screening non-participants 2.31 (1.82, 2.94) 1.77 (1.47, 2.13) 2.54 (1.82, 3.53) 1.85 (1.44, 2.38)
HRs adjusted for calendar time in time scale and the covariates age at diabetes detection, calendar year of diabetes detection, sex and SES reported in the
1990 census
SESs imputed for n = 1561 individuals who had missing information
Unconfirmed screen-positive individuals had only a diabetic screening result, whereas confirmed screen-detected individuals had a diabetic screening
result and a medical or prescription record of diabetes within 1 year. Those with clinically detected diabetes were identified in five sources of medical and
prescription records, unrelated to screening
Ref, reference population
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clinical course and better prognosis [26] has not previously
been explored specifically for diabetes. However, our data
indicate that this concept may be equally important for
diabetes screening as it is for several cancers [27]. It appears
that slowly progressing hyperglycaemia and diabetes may be
associated with better health outcomes than more rapidly
progressing disease, as indicated by the fact that clinically
detected individuals with diabetes who had normoglycaemia
at their previous VIP examination had worse health outcomes
after diagnosis than those who had been non-diabetic
hyperglycaemic or who had had diabetes-indicative OGTT
results. However, those who had diabetic or non-diabetic
hyperglycaemia at their previous screening should have
received lifestyle advice and referrals to continued care, which
could have also contributed to a better prognosis after
diagnosis. In addition, the mean time to diabetes detection
from screening was about 4 years longer for those with
previous normoglycaemia, and we cannot know for how long
they would have lived with hyperglycaemia prior to their
diagnosis. Ideally, we would have liked to test the contribution
of length time bias by adjusting for health status and
biomarkers for diabetes severity at the time of detection, but
these data were not available. When we adjusted for several
biomarkers associated with general health status measured at
the previous screening, the estimates were attenuated, which
supports a role of length time bias, but the analysis has
limitations so a cautious interpretation is warranted.
The third source of bias is lead time bias. Although we adjust-
ed for age at detection in the analyses, we cannot disregard the
fact that there may be residual bias from differences in lead time
as screen-detected individuals had on average a 1.5 years longer
observation time owing to being detected earlier in the disease
course than those with clinically detected diabetes [28, 29].
Taken together, these data suggest that there may be a
positive effect of early detection and treatment due to
screening on survival and health outcomes after a diagnosis
of diabetes, but howmuch is not within the scope of this study
to determine. These results are in line with those from
ADDITION-Denmark [7].
We found that it was more common for a diabetes-indicative
OGTT result to remain unconfirmed than to be confirmed within
1 year, which is in line with findings from previous studies [8]. In
this study, unconfirmed screen-positive individuals were overall
younger and had consistently better health at the point of the
positive diabetic screening result than confirmed screen-
detected individuals with diabetes. They also had lower inci-
dence rates of CVD and renal disease, a considerably lower
incidence rate of retinopathy, but a higher mortality rate. There
is reason to believe that some of the difference in retinopathy and
renal disease rates is due to surveillance bias as individuals with
confirmed diabetes are more likely to be tested for these condi-
tions, but this is less likely to be the case for CVD events and is
not the case for deaths. These results indicate that unconfirmed
screen-positive individuals would potentially benefit from treat-
ment for themanagement of blood glucose levels and related risk
factors in order to reduce the risk of CVD [30].
The primary strengths of this studywere the large population
size and the fact that we were able to study a model for an
organised whole population-based screening programme for
diabetes with follow-up for over 20 years that included partic-
ipants as young as age 30 years. The main limitations were the
relatively short follow-up period and that we could not assess
the association between screening in general and health out-
comes after diagnosis owing to the non-randomised design
(lack of a non-screening control group). The diagnostic criteria
for diabetes were revised during the study period when the
fasting glucose level threshold in the OGTTwas lowered from
7.8 mmol/l to 7.0 mmol/l in 1999 [31], although it was unclear
when this revision was implemented in the VIP, meaning that
some individuals may have been misclassified. However, there
were only ten screen-detected individuals (data not shown)
within this range between 1992 and 1998, and since all diabetes
cases in this group were confirmed by another source within
1 year, the resulting bias is likely to be limited. The median
follow-up time was relatively short at 6.2–7.8 years, but the
results were similar even after 10 years’ follow-up. We did
not have access to data on marital status and income, variables
that have been associated with propensity to participate in
screening [12], but we were able to control for SES.
Individuals with clinically detected diabetes were identified
from five different sources, and as a consequence systematic
information on biomarkers associated with severity of diabetes
at time of diagnosis was unavailable.
In conclusion, in this population-based study of screen- and
clinically detected diabetes, we found that screen-detected
individuals were detected at a younger age, and may have
better survival and lower rates of CVD, renal disease and
retinopathy than those who were clinically detected.
Data availability Data from the Västerbotten Intervention Study may
be obtained from the corresponding author on reasonable request; all
linked datasets may be obtained separately from the various register
holders, as listed in the Methods section.
Funding This work was supported by the Medical Research Council
(MC_UU_12015/4), the Swedish Council for Working Life and Social
Research (FAS 2006_1512) and the Swedish Research Council
(2006-21576-36119-666). The VIP is financed by Västerbotten County
Council. ALF is supported by the Raymond and Beverly Sackler
Foundation through Churchill College, Cambridge.
Duality of interest SJG declares receipt of an honorarium and
reimbursement of travel expenses from Eli Lilly associated with membership
of an independent data-monitoring committee for a randomised trial of a
medication to lower glucose, and receipt of honoraria for speaking at
postgraduate educational meetings from Janssen and Astra Zeneca. All other
authors declare no duality of interest associated with this manuscript.
2208 Diabetologia (2017) 60:2200–2209
Contribution statement ALF designed the analysis plan, performed the
data analyses, interpreted the results and drafted and critically revised the
manuscript. OR conceived the study question, obtained the data, contributed
to the analysis plan, interpreted the results and critically revised the
manuscript. SJG contributed to the analysis plan, interpreted the results and
critically revised the manuscript. LWandMN coordinated the data collection
in the Västerbotten Intervention Study, contributed to the analysis plan and
critically revised the manuscript. EF and PW contributed to the analysis plan
and critically revised the manuscript. All authors have approved the final
version of the manuscript. OR is the guarantor of this work.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. International Diabetes Federation (2015) IDF diabetes atlas, 7th edn.
Available from www.diabetesatlas.org/. Accessed 31 July 2017
2. Simmons RK, Echouffo-Tcheugui JB et al (2012) Screening for
type 2 diabetes and population mortality over 10 years
(ADDITION-Cambridge): a cluster-randomised controlled trial.
Lancet 380:1741–1748
3. Simmons RK, Griffin SJ, Witte DR, Borch-Johnsen K, Lauritzen T,
Sandbæk A (2017) Effect of population screening for type 2 diabe-
tes and cardiovascular risk factors on mortality rate and cardiovas-
cular events: a controlled trial among 1,912,392 Danish adults.
Diabetologia DOI 10.1007/s00125-017-4323-2
4. Simmons RK, Rahman M, Jakes RW et al (2011) Effect of popu-
lation screening for type 2 diabetes on mortality: long-term follow-
up of the Ely cohort. Diabetologia 54:312–319
5. Rahman M, Simmons RK, Hennings SH, Wareham NJ, Griffin SJ
(2012) How much does screening bring forward the diagnosis of
type 2 diabetes and reduce complications? Twelve year follow-up
of the Ely cohort. Diabetologia 55:1651–1659
6. Jansson SP, Andersson DK, Svardsudd K (2016) Mortality and
cardiovascular disease outcomes among 740 patients with new-
onset type 2 diabetes detected by screening or clinically diagnosed
in general practice. Diabet Med 33:324–331
7. Simmons RK, Griffin SJ, Lauritzen T, Sandbæk A (2017) Effect of
screening for type 2 diabetes on risk of cardiovascular disease and
mortality: a controlled trial among 139,075 individuals diagnosed
with diabetes in Denmark between 2001 and 2009. Diabetologia
DOI 10.1007/s00125-017-4299-y
8. Engelgau MM, Narayan KM, Herman WH (2000) Screening for
type 2 diabetes. Diabetes Care 23:1563–1580
9. Huang Y, Cai X, Mai W, Li M, Hu Y (2016) Association between
prediabetes and risk of cardiovascular disease and all cause mortal-
ity: systematic review and meta-analysis. BMJ 355:i5953
10. Norberg M, Wall S, Boman K, Weinehall L (2010) The
Västerbotten Intervention Programme: background, design and im-
plications. Glob Health Action 3:4643
11. Blomstedt Y, Norberg M, Stenlund H et al (2015) Impact of a
combined community and primary care prevention strategy on all-
cause and cardiovascular mortality: a cohort analysis based on 1
million person-years of follow-up in Västerbotten County, Sweden,
during 1990-2006. BMJ Open 5:e009651
12. Norberg M, Blomstedt Y, Lonnberg G et al (2012) Community
participation and sustainability – evidence over 25 years in the
Västerbotten Intervention Programme. Glob Health Action 5:1–9
13. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A
(2009) The Swedish personal identity number: possibilities and pit-
falls in healthcare andmedical research. Eur J Epidemiol 24:659–667
14. Ludvigsson JF, Almqvist C, Bonamy AK et al (2016) Registers of
the Swedish total population and their use inmedical research. Eur J
Epidemiol 31:125–136
15. World Health Organization and International Diabetes Federation
(2006) Definition and diagnosis of diabetes mellitus and intermedi-
ate hyperglycaemia: report of a WHO/IDF consultation. World
Health Organization, Geneva
16. Rolandsson O, Norberg M, Nystrom L et al (2012) How to diag-
nose and classify diabetes in primary health care: lessons learned
from the Diabetes Register in Northern Sweden (DiabNorth). Scand
J Prim Health Care 30:81–87
17. Gudbjornsdottir S, Cederholm J, Nilsson PM, Eliasson B, Steering
Committee of the Swedish National Diabetes Register (2003) The
National Diabetes Register in Sweden: an implementation of the St.
Vincent Declaration for Quality Improvement in Diabetes Care.
Diabetes Care 26:1270–1276
18. Swedish National Diabetes Register (NDR). Annual reports 2007–2013.
Available from www.ndr.nu/#/arsrapport [in Swedish]. Accessed 31
July 2017
19. Wallerstedt SM, Wettermark B, Hoffmann M (2016) The first de-
cade with the Swedish prescribed drug register—a systematic re-
view of the output in the scientific literature. Basic Clin Pharmacol
Toxicol 119:464–469
20. Swedish National Board of Health and Welfare. The National
Patient Register. Available from www.socialstyrelsen.se/register/
halsodataregister/patientregistret/inenglish. Accessed 31 July 2017
21. Robles SC, Marrett LD, Clarke EA, Risch HA (1988) An applica-
tion of capture-recapture methods to the estimation of completeness
of cancer registration. J Clin Epidemiol 41:495–501
22. Swedish National Board of Health and Welfare. The Cause of
Death Register. Available from www.socialstyrelsen.se/register/
dodsorsaksregistret [in Swedish]. Accessed 31 July 2017
23. Waller G, Janlert U, Norberg M, Lundqvist R, Forssen A (2015)
Self-rated health and standard risk factors for myocardial infarction:
a cohort study. BMJ Open 5:e006589
24. Herman WH, Ye W, Griffin SJ et al (2015) Early detection and treat-
ment of type 2 diabetes reduce cardiovascular morbidity and mortality:
a simulation of the results of the Anglo-Danish-Dutch Study of
Intensive Treatment in People With Screen-Detected Diabetes in
Primary Care (ADDITION-Europe). Diabetes Care 38:1449–1455
25. Dugue PA, Lynge E, Rebolj M (2014) Mortality of non-participants
in cervical screening: register-based cohort study. Int J Cancer 134:
2674–2682
26. Zelen M, Feinleib M (1969) On theory of screening for chronic
diseases. Biometrika 56:601–614
27. Spratt JS, Meyer JS, Spratt JA (1996) Rates of growth of human
neoplasms: part II. J Surg Oncol 61:68–83
28. Duffy SW, Nagtegaal ID, Wallis M et al (2008) Correcting for lead
time and length bias in estimating the effect of screen detection on
cancer survival. Am J Epidemiol 168:98–104
29. Maurice A, Evans DG, Shenton A et al (2006) Screening younger
women with a family history of breast cancer—does early detection
improve outcome? Eur J Cancer 42:1385–1390
30. Li G, Zhang P, Wang J et al (2014) Cardiovascular mortality, all-
cause mortality, and diabetes incidence after lifestyle intervention
for people with impaired glucose tolerance in the Da Qing Diabetes
Prevention Study: a 23-year follow-up study. Lancet Diabetes
Endocrinol 2:474–480
31. World Health Organization (1999) Definition, diagnosis and classi-
fication of diabetes mellitus and its complications. Report of a
WHO consultation. Part 1: Diagnosis and classification of diabetes
mellitus. Geneva: World Health Organization
Diabetologia (2017) 60:2200–2209 2209
